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ABSTRACT 
Background: The high survival rate for childhood acute lymphoblastic leukaemia (ALL) is counterbalanced 
by the burden of toxicities, but reported frequencies vary widely across studies partly due to diverse 
toxicity definitions.  
Method: Using Delphi method, 15 international childhood ALL study groups scrutinised ALL protocols to 
address 14 acute toxicities that are serious, but too rare to be addressed comprehensively within any single 
group or regarded to need consensus definitions for reliable incidence comparisons: hypersensitivity to 
asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, arterial hypertension, 
posterior reversible encephalopathy syndrome, seizures, depressed level of consciousness, methotrexate-
related stroke-like syndrome, peripheral neuropathy, high-dose methotrexate related nephrotoxicity, 
sinusoidal obstructive syndrome, thromboembolism, and Pneumocystis jirovecii pneumonia. 
Results: None of the ALL protocols addressed all 14 toxicities, no two protocols shared identical definitions 
of all toxicities, and no toxicity definition was shared by all protocols. Consensus definitions were obtained 
for all 14 toxicities. 
Conclusion: In the overall evaluation of outcome of ALL therapy, these expert opinion-based definitions will 
allow reliable comparisons of acute toxicity frequencies and severities across treatment protocols and 
facilitate international research on aetiology, guidelines for treatment adaptation, preventive strategies, 
and development of consensus algorithms for reporting of ALL therapy outcome that balance toxicity and 
antileukaemic efficacy.  
 
KEY WORDS: Acute lymphoblastic leukaemia, child, chemotherapy, Delphi method, toxicity. 
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INTRODUCTION 
Acute lymphoblastic leukaemia (ALL) accounts for 25% of all childhood cancers and has leapt from being 
universally fatal two generations ago to having five year overall survival rates above ninety percent with the 
best contemporary treatment.1 However, a substantial number of patients experience severe fatal or life-
long toxicities. 2 The frequency of these toxicities vary widely across study protocols (webappendix pages 2, 
5, 7, 8, 10, 11, 13, 15, 18, and 19), which reflects not only the treatment intensities, but also diverse toxicity 
definitions and strategies for toxicity capture and reporting, making meaningful comparisons of toxicity 
risks impossible.  
 
The progressive intensification of ALL therapy in recent decades has led to a situation where, for good risk 
patients, the chance of treatment-related death may now equal the chance of leukaemic relapse. 3 
Accordingly, trials no longer aim only to introduce more powerful antileukaemic agents, but in parallel 
focus on minimising toxicity. Evaluating the success of this approach depends on robust measurement of 
the toxicity burden within different arms of a trial, between different trials internationally, and between 
patient subsets defined by clinical features or germline DNA variants. 4 
 
Definitions for most organ toxicities already exist, and the United States National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE)5 is widely used. However, many toxicities are described in 
very general terms in CTCAE, and the toxicity definitions were not developed to meet the specific needs 
associated with childhood ALL therapy. In addition, the toxicity grades that are currently captured and 
reported vary across protocols. Finally, various definitions are used for several toxicities (webappendix page 
24), and consensus definitions across ALL protocols are lacking. Recognising the need for international 
collaboration on this issue, the Ponte di Legno consortium (PdL) established a toxicity working group 
(PTWG) to address serious adverse events associated with childhood ALL therapy. The PdL consortium aims 
to improve outcomes of childhood ALL.1  It encompasses the Associazione Italiana Ematologia ed Oncologia 
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Pediatrica (AEIOP; Italy), the Berlin-Frankfurt-Münster study group (BFM; Germany), the German Co-
operative Study Group for treatment of Acute Lymphoblastic Leukemia (COALL; Germany), the US Childrens 
Oncology Group (COG; USA), the Czech Working Group for Pediatric Hematology (CPH; Czech Republic), the 
Dutch Childhood Oncology Group (DCOG; Holland), the Dana Farber Cancer Institute consortium (DFCI; 
Boston, USA), the European Organisation for Research and Treatment of Cancer (EORTC; Belgium and 
France), the French Acute Lymphoblastic Leukemia study group (FRALLE; France), the Israel National Study 
(INS; Israel), the Japanese Pediatric Leukemia Study Group (JPLSG; Japan), the Nordic Society for Paediatric 
Haematology and Oncology (NOPHO; Denmark, Finland, Iceland, Lithuania, Norway, Sweden), St Jude 
Children’s Research Hospital (SJCRH; USA), the Taiwan Pediatric Oncology Group (TPOG; Taiwan), and the 
United Kingdom Acute Lymphoblastic Leukaemia and Lymphoma Trial Group (UKALL; United Kingdom).  
 
As a first step, the PTWG aimed to obtain consensus definitions of 14 prioritised acute toxicities. We report 
here the process and the final definitions that have been approved by the involved PdL ALL groups. These 
definitions will be crucial for future reliable comparison of toxicity data emerging from various ALL 
treatments, for collaborative research addressing risk factors including host genome variants, and for 
comparison of strategies for prevention or treatment of toxicities.  
 
METHODS 
Based on the need for international definitions for acute toxicities that are serious, but either too rare to be 
addressed comprehensively within any single ALL group or that need consensus definitions for reliable 
comparison of incidences and outcome, representatives from 15 PdL groups initially listed all acute 
toxicities that they regarded to be relevant for consideration by the PTWG (webappendix page 22, table 
A1). Following initial discussions, it was decided that toxicities that were almost universally reversible and 
in addition sufficiently common to be explored within a single ALL group, such as mucositis, bone-marrow 
and immune suppression, febrile neutropenia, skin rashes, hyperglycaemia, and several transient organ 
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failures should not be pursued by the PTWG. Among the remaining listed toxicities (webappendix page 22, 
table A1), “treatment-related mortality”, “invasive fungal infections” apart from Pneumocystis jirovecii 
pneumonia, and “transfer to intensive care unit” were deferred, since the former two either have been6 or 
currently are being addressed by other international working groups, and the latter was regarded as being 
too influenced by local logistics and resources. Furthermore, toxicities that have multiple and complex 
causes (such as hepatic failure) were not regarded as candidates for PTWG consensus definitions, although 
they may be relevant for future prospective registration to quantify and qualify the burden of 
antileukaemic therapy. Finally, several toxicities that were serious but already defined and graded by CTCAE 
with definitions suitable for children with ALL were not addressed (webappendix page 22, table A1). 
 
Search strategy and selection criteria 
Since the pathogeneses and natural histories for most of the remaining 14 prioritised toxicities are poorly 
understood from a biological point of view, a Delphi process was chosen for obtaining expert opinion based 
consensus definitions (Figure 1). 7,8 For each of the 14 toxicities, ad hoc working groups (AWG), including a 
chair for each AWG, were established with initial representation of experts from at least three of the 15 
involved ALL groups, but subsequently expanded after each face-to-face plenary PTWG meeting 
(webappendix page 22, table A1). Each AWG reviewed i) the current literature on their toxicity with special 
focus on ALL cohort publications, and ii) the toxicity sections of 13 treatment protocols currently used by 
PdL groups. In addition, co-author MK added information on the Japanese ALL protocols, as they were not 
available in English versions. AEIOP (Italy) and BFM (Germany and Austria) share almost identical ALL 
treatment protocols, including toxicity sections, which subsequently have been adopted by CPH (Czech) and 
INS (Israeli) groups. Each AWG’s results and considerations were debated within their collaborative ALL 
group and at three consecutive face-to-face plenary meeting including all AWGs during the International 
BFM annual meeting in Prague April 2014, the American Society of Hematology annual meeting in San 
Fransisco December 2014, and the International BFM annual meeting in Budapest May 2015 (Figure 1). 
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These face-to-face discussions were open to other individuals from the Ponte di Legno consortium, even if 
they were not directly involved in developing the final toxicity definitions. Based on discussions at these 
meetings and comments from the involved PdL ALL groups, the definitions (Table 1) and the webappendix 
were finalised. The definitions were then approved by all the groups. 
 
RESULTS 
Although the ALL protocols all have sections on treatment-related toxicities, none of the protocols address 
all of the 14 listed toxicities in this report, and when addressed they use various definitions (webappendix 
page 24, table A2). Furthermore, whilst one specific toxicity can be highlighted by one ALL treatment 
protocol with extensive description of that toxicity (e.g. posterior reversible encephalopathy syndrome 
(PRES)), other protocols may not mention that toxicity at all. Many protocols agree on individual toxicity 
definitions and grading, especially when CTCAE is applied, 5 but no two protocols share identical definitions 
of all toxicities, and no toxicity definition is shared by all protocols. Some protocols request data capture of 
any grade of a toxicity, whereas others only address the most severe grades. In addition, the consequence 
of occurrence of a specific toxicity varies by protocol from complete withdrawal of an antileukaemic agent 
(e.g asparaginase after pancreatitis) to no consequences, including acceptance of re-exposure, although not 
always specifically stated (see webappendix). Detailed discussion of the toxicities is presented in the 
webappendix, and a summary of some of the key disparities and discussion points are described below. 
 
Hypersensitivity to asparaginase 
Allergic reactions to asparaginase are frequent.9,10 All protocols address hypersensitivity, but only a few 
address silent inactivation, and then with various definitions of trough levels and time-points for 
measurements, and none address allergic-like reactions (e.g. vomiting, stomach ache, or rash) without 
inactivation of asparaginase or indications for change in therapy (webappendix page 2). There was PTWG 
consensus that definitions of hypersensitivity and silent inactivation as well as allergy-like reactions were 
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needed, although each may pose practical clinical challenges. All but one group use pegylated asparaginase 
(Peg-Asp) as front-line therapy. Since Peg-Asp becomes inactivated in virtually all patients with and allergic 
reaction irrespective of its severity, 9 any degree of hypersensitivity should logically lead to a change to 
Erwinia asparaginase. 10 In addition to the definition of asparaginase hypersensitivity, the PTWG defined 
silent inactivation in patients without clinical allergy as trough asparaginase activity levels below lower level 
of quantification (LLQ, preferably measured in two independent samples), i.e. i) a day 7 asparaginase 
activity level <100 IU/L and/or a day 14 level <LLQ in case of biweekly PEG-Asp, and ii) a 48 hours post-dose 
level <LLQ in case of Erwinia asparaginase (2-3 times a week) (Table 1 and webappendix page 2). 
  
Hyperlipidaemia 
Both asparaginase and glucocorticosteroids can cause transient and occasionally severe 
hypertriglyceridaemia. This may lead to (albeit so far undocumented) toxic complications (e.g. thrombosis 
and cardiovascular late effects). 11 However, only a few protocols address this toxicity, mostly without a 
clear definition, and only one recommends routine monitoring of serum triglycerides for selected patients. 
There is PTWG consensus on defining severity of hypertriglyceridaemia based on levels, and also that 
routine monitoring should currently only take place as part of a research strategy.  
 
Osteonecrosis 
Osteonecrosis (ON) is a very common side effect of ALL therapy, and all protocols address although with 
diverse definitions 12 and guidelines for further glucocorticosteroid therapy, 12 and none clarify the role or 
interpretation/classification of imaging. 13 In spite of its limitations, all but one protocol used the CTCAE for 
clinical grading. There is PTWG consensus that MRI should be applied for confirmation of clinically 
symptomatic disease rather than for screening all patients, and that the latter should only be used 
currently within a research project.  
  
8 
 
Asparaginase-associated pancreatitis 
Asparaginase-associated pancreatitis (AAP) has a low direct mortality, but is one of the most frequent 
causes of discontinuation of asparaginase therapy, which could increase risk of relapse. 14 All but one ALL 
protocol provide a definition of AAP with grading using either the CTCAE criteria or some modification of 
the Atlanta criteria, 15 i.e. i) abdominal pain suggestive of acute pancreatitis, ii) serum amylase at or above 
2-3 times upper normal limit, and iii) imaging findings characteristic of acute pancreatitis, however varying 
as to whether two or three criteria should be fulfilled. Some protocols recommended measurements of 
both amylase and lipase, since the latter is more specific and sensitive. Protocols with extended use of 
asparaginase generally recommend truncation of asparaginase therapy only in cases of severe AAP. 
 
Arterial hypertension 
Arterial hypertension is common, especially during the first months of antileukaemic therapy. 16 However, 
none of the ALL protocols address arterial hypertension as an isolated phenomenon, instead mentioning it 
only in association with PRES. There was PTWG consensus that the American Academy of Pediatrics 17 and 
the CTCAE guidelines provide classifications of hypertension that are adaptable to its generally transient 
occurrence during ALL therapy (Table 1).  
 
Posterior reversible encephalopathy syndrome 
Although PRES is a clinico-radiological entity frequently seen during the first months of ALL therapy 
reflecting disturbances of cerebrovascular autoregulation and inconsistently characterised by headache, 
altered mental status, seizures, and visual disturbances, 18 seven protocols do not address it at all, and only 
one addresses it in detail. When addressed, all protocols apply the CTCAE grading used for any 
encephalopathy in spite of its limited usefulness for PRES. Except for postponing intrathecal therapy until 
symptoms resolve, no antileukaemic treatment modifications are recommended in any of the protocols. 
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The PTWG consensus definition of PRES addresses the essential clinical and imaging characteristics as well 
as supportive but non-mandatory findings. 
 
Seizures 
Seizures occur in approximately 10% of childhood ALL patients. 19 Most ALL protocols grade seizures 
clinically according to CTCAE, which does not require electroencephalography and excludes absence 
seizures which are anyway rare in childhood ALL. Seizures can occur both as an isolated symptom, together 
with various other CNS toxicities (e.g. intracranial haemorrhage or thrombosis, PRES, methotrexate (MTX) 
related stroke-like syndrome (MTX-SLS)), and second to electrolyte and metabolic disturbances, and 
infections. The PTWG decided not to include causation in the definition, but will address this complexity in 
registration of seizures in the future.   
 
Depressed level of consciousness 
The protocols provide grading for encephalopathy in general, but not specifically in the context of 
decreased consciousness or even coma, potentially reflecting the complexity of both classification of the 
toxicity itself and its multiple aetiologies such as infection, altered body temperature, electrolyte and 
metabolic disturbances, vascular or neurologic complications, and direct toxic effects of chemotherapy. The 
PTWG consensus definition is based on clinical findings only. 
 
MTX-related stroke-like syndrome 
MTX-SLS, which is characterised by focal neurological deficits or hemiparesis and often accompanied by 
disturbances in speech and/or affect, develops within two to three weeks after MTX administration and 
waxes and wanes over the subsequent hours to days. 20,21 All but one protocol provided grading for 
encephalopathy, although not specifically for MTX-SLS, using CTCAE or the US Eastern Cooperative 
Oncology Group criteria. Only five protocols address this syndrome, only one of these describes the 
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characteristic symptoms in detail, and only a few provide (various) guidelines for MTX re-exposure once the 
MTX-related neurotoxicity has resolved. Although MRI will not always be able to confirm MTX-SLS, it is 
included in the consensus definition due to the characteristic changes often seen, and its ability to 
distinguish between MTX-SLS and PRES.  
 
Peripheral neuropathy 
Peripheral motor and/or sensory neuropathy is common and generally caused by vincristine and in that 
case nearly always reversible. 22 No protocols recommend discontinuation of VCR except in cases of 
paralysis (occasionally caused by Charcot-Marie-Tooth disease), but several protocols recommend dose 
reduction in CTCAE grade 3-4 cases of paraesthesia or motor paralysis. This toxicity is addressed by all 
treatment protocols with the CTCAE grading, except for one group applying the Balis scale, 23 and the CTCAE 
grading was agreed upon by PTWG with minor modifications.  
 
High-dose methotrexate related nephrotoxicity 
All protocols that include administration of high-dose MTX (2.5-5.0 g/m2) have clear, although diverse, 
guidelines for hydration, alkalinisation, and folinic acid rescue. They differ in their definition of delayed MTX 
elimination both with respect to MTX concentrations and time points from initiation of the MTX infusion. In 
cases of severely delayed elimination of MTX, less than half of the protocols include guidelines for the use 
of carboxypeptidase that enzymatically breaks down MTX to non-toxic metabolites. 24 Due to the very 
strong association between renal impairment and delayed MTX clearance, both parameters were included 
in the consensus definition.  
 
Sinusoidal obstructive syndrome 
The sinusoidal obstructive syndrome (SOS) or veno-occlusive disease is most commonly seen after 
haematopoietic stem cell transplantation and during 6-thioguanine containing maintenance therapy, but 
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rarely with 6MP-based maintenance therapy. 25 Although the general risks of hyperbilirubinaemia and 
elevations of aminotransferases during ALL therapy are mentioned in most of the ALL protocols, SOS is not 
included in CTCAE and only two of the ALL protocols specifically addressed SOS, with only one including a 
SOS definition. The PTWG consensus definition is based on combinations of at least three of five clinical 
findings and does not require imaging, although this may be of diagnostic benefit in selected cases. 
 
Thromboembolism  
The majority of the protocols address thromboembolic (TE) events, with all grading them according to 
CTCAE, but varying with respect to which grades are to be reported as severe adverse events. In cases of TE 
during asparaginase therapy, all six protocols that address the issue recommend re-exposure with 
asparaginase once the patient’s clinical condition has stabilised and low molecular weight heparin has been 
instituted. 26 The PTWG consensus definition of TE incorporates both localisation and severity of symptoms. 
 
Pneumocystis jirovecii pneumonia 
The high risk of Pneumocystis jirovecii pneumonia (PJP) when PJP prophylaxis is not given during childhood 
ALL therapy is recognised in all protocols, but they differ in their dosage of prophylactic co-trimoxazole 
prescribed and in the required diagnostic criteria. 27 The PTWG consensus definition distinguishes between 
confirmed and probable PJP. 
 
Discussion 
“This is not the end, it is not even the beginning of the end, but it is, perhaps, the end of the beginning” 
(Winston Churchill, November 1942).  
 
In childhood ALL, the term event-free survival traditionally encompasses five clear-cut events, namely 
death during induction, resistance to first-line therapy, relapse of ALL, non-leukaemic death during clinical 
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remission, and development of a second cancer. 1 While this composite measure of treatment outcome 
seemed sufficient, when life expectancy for children with ALL was poor, it falls short of current needs. Thus, 
while many patients with a late relapse or a second cancer have a fair chance of being cured by second line 
therapy, we cannot currently reverse their chronic toxicities. Each year thousands of children around the 
world are cured following ALL. However, many of them will have been burdened by severe acute toxicities 
that may cause permanent organ damage, such as osteonecrosis, chronic pancreatitis, thrombosis, and 
neurotoxicity, and even more will develop additional severe late effects that challenge their ability to 
establish and live a normal adult life. 28,29  
 
Although the cumulative risk of each of the 14 acute toxicities addressed in this report is in the order of five 
to ten percent or less, approximately half of all patients will be affected by at least one of these significant 
acute toxicities. 30 Thus, in the overall evaluation of ALL treatment protocols, there is a need for 
development of strategies to quantify the overall acute and long-term burden of therapy and balance it 
against event-free survival rates. This will require uniform reporting in ALL trials of both life-threatening 
and fatal toxicities as well as of toxicities that are associated with significant late effects.  
 
If we are to develop evidence-based preventive interventions towards these, it requires i) consensus 
toxicity definitions for comparison of outcome across protocols, ii) common strategies for toxicity capture 
and registration, and iii) international collaboration to identify host genome variants and exposures (e.g. 
antileukaemic treatment, co-medication, food) associated with the risk of specific toxicities. 
 
Not all toxicity definitions presented in table 1 are clear-cut, which primarily reflects their uncertain 
pathophysiology. Furthermore, several toxicities can involve overlapping symptoms, e.g. from the central 
nervous system, making precise classification challenging. In addition, guidelines for interventions can be 
directed towards the symptom (e.g. seizures or hypertension due to PRES) or the toxicity as such (e.g. MTX-
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SLS). Accordingly, future registrations of certain organ toxicities should allow entry of both separate 
symptoms (e.g. seizures) and a putative syndrome (e.g. PRES).  
 
The toxicity definitions listed in this report were developed after review of the existing literature, current 
ALL protocol, and use of the Delphi method to develop expert consensus. 7,8 These definitions are a starting 
point for developing evidence-based guidelines regarding optimal management and prevention strategies. 
Although the definitions are supported by the PdL ALL groups and should be widely applicable, their clinical 
and biological validity will emerge in parallel with their implementation and a deeper understanding of the 
pathogenesis of the toxicities, facilitated by relevant in vitro and animal models and international research 
collaboration.  
 
The current CTCAE toxicity criteria are mostly clinical and their grading is generally based on a five grade 
scale (asymptomatic/mild; moderate/symptomatic rarely requiring intervention; severe/limiting activity of 
daily living but not life-threatening; life-threatening with urgent intervention needed; death). The CTCAE 
criteria benefit from their long history of use, and from the standardization of number of grades and 
uniformity of definitions. However, they are not specifically adapted to the administered anticancer 
therapy, and some toxicities (e.g. osteonecrosis and infertility) are never life-threatening or fatal, thus 
reducing the number of grades. Furthermore, the inclusion of medical intervention in several classifications 
is controversial, since it indicates that intervention is needed for a certain grade of toxicity, and the 
definition may on the other hand reclassify a patient, if it is decided to refrain from intervention due to 
local practice or patient preference rather than just toxicity severity. Finally, the definition of toxicity grades 
should also be coherent with re-exposure guidelines for ALL therapy (e.g. asparaginase in cases of mild 
AAP).  
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Due to national regulations some trial groups will be mandated to continue to register toxicities according 
to certain guidelines, such as the CTCAE (currently under revision) 5 in the US. These ALL groups will need to 
consider toxicity capture and registration strategies that cover both systems in order to allow future 
reporting of their data in a format that allow reliable comparison of the toxicity profile with ALL groups that 
use the PdL toxicity definitions.   
 
The subsequent, but equally challenging, goal for the PTWG is now to develop common strategies for 
toxicity capture and registration, since targeting selected toxicities may favour their capture at the expense 
of non-targeted, but routinely registered, CTCAE graded toxicities, even though the latter toxicities may be 
equally important clinically.31 In addition, the PTWG will address guidelines for drug re-exposures, explore 
the impact of host genome variants on toxicity risks, and develop consensus algorithms that balance 
toxicity and efficacy in composite evaluations of the outcome of ALL treatment. Thus, although many 
toxicities emerging during childhood ALL therapy can be far more difficult to capture than the classical five 
treatment failures, they are as critical to include in future registration and in intervention trials to improve 
the outcome of childhood ALL. 
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LEGEND TO TABLE AND FIGURE 
Table 1: * = Details on each toxicity are provided in the webappendix; ADL = Activity of daily living; APP = 
asparaginase-associated pancreatitis; CVL = Central venous line; CT = Computerised tomography; CTCAE.03 
= National Cancer Institute Common Terminology Criteria for adverse events version 4.03; DBP = diastolic 
blood pressure; DWI = Diffusion weighted imaging; LLQ = Lower level of quantification; μM = micromolar; 
MRI = Magnetic resonance imaging; MTX = methotrexate; PEG = Pegylated; PJP = Pneumocystis jirovecii 
pneumonia; PRES = Posterior reversible encephalopathy syndrome; SBP = Systolic blood pressure; SOS = 
Sinusoidal syndrome; TE = Thromboembolism; UNL= Upper normal limit; US = Ultrasound. 
Figure 1: Delphi process to reach consensus definitions for 14 toxicities. ALL = Acute lymphoblastic 
leukemia; AWG = Ad hoc toxicity working group; CTCAE = National Cancer Institute Common Terminology 
Criteria for Adverse Events; PTWG = Ponte di Legno Toxicity Working Group;  
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WEBAPPENDIX 
Detailed document covering the 14 toxicities addressed by the Ponte di Legno Toxicity Working Group.  
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Table 1. Definitions and gradings of fourteen acute toxicities associated with treatment of childhood acute lymphoblastic leukaemia* 
Toxicity  Consensus definition 
Hypersensitivity 
to asparaginase 
An adverse local or general response from exposure to Asparaginase characterised by flushing, rash, urticaria, drug fever, dyspnoea, symptomatic 
bronchospasm, oedema/angiooedema, hypotension and/or anaphylaxis. Grading:  
1.Mild: transient flushing or rash, drug fever <38o C,  
2.Severe: drug fever >38o C; allergy-related edema/angiooedema; dyspnoea and/or symptomatic bronchospasm with or without urticarial; and/or 
hypotension and anaphylaxis with indication for Asparaginase infusion interruption and parenteral medication (e.g. antihistamines, glucocorticosteroids). 
Silent 
inactivation of 
asparaginase 
No clinical allergy, but trough Asparaginase activity levels below lower level of quantification (preferably measured in two independent samples). In case of 
biweekly PEG-Asparaginase, a day 7 Asparaginase activity level <100 IU/L and/or a day 14 level <LLQ. In case of Erwinia Asparaginase (2-3 times a 
week) a 48 hours post-dose level <LLQ 
Allergic-like 
reaction to 
asparaginase 
Intolerance (e.g. vomiting, stomach ache, or rash) without inactivation of asparaginase, usually occurring later in the infusion than real Asparaginase allergy 
that in general occurs at the first drops.  
Note: Distinction between hypersensitivity and allergic-like reactions is critical, since clinical hypersensitivity (even mild) is closely associated with 
Asparaginase inactivation. Asparaginase activity measurements may distinguish and guide decision on switch to other Asparaginase preparations. 
Hyperlipidemia 
Triglycerides/cholesterol above UNL. Grading:  
1.Mild: triglycerides/cholesterol <10 times UNL,  
2.Moderate:  triglycerides/cholesterol 10-20 times UNL,  
3.Severe:  triglycerides/cholesterol >20 times UNL.  
Note: Routine measurements only as part of research protocols. Dose modification based only on laboratory findings is not recommended. 
Osteonecrosis 
Osteonecrosis results from the temporary or permanent loss of the blood supply to the bones, which can cause pain, limitation in ADL, and may result in 
collapse of a articulating surface with enhanced pain and development of arthritis. It should be confirmed by magnetic resonance imaging (MRI). Grading: 
1.Asymptomatic with findings only by MRI,  
2.Symptomatic, not limiting or only slightly limiting self-care ADL. Lesions only outside joint lines in non-weight-bearing bones, 
3.Symptomatic, not limiting or only slightly limiting self-care ADL. Lesions in weight-bearing bones or affecting joint lines in non-weight-bearing bones, 
4.Symptomatic with deformation by imaging of one or more joints and/or significantly limiting self-care ADL. 
Asparaginase-
associated 
pancreatitis 
At least two of three features must be fulfilled: i) abdominal pain strongly suggestive of pancreatitis, ii) serum lipase or amylase e3 times UNL, iii) 
characteristic imaging findings of pancreatitis (US/CT/MRI). Re-exposure should only be considered in mild cases. Grading: 
1.mild:  symptoms and enzyme elevations >3 times UNL that last <72 hours, 
2.severe: symptoms and enzyme elevations above >3 times UNL that last >72 hours or haemorrhagic pancreatitis or pancreatic abcess or cyst, 
3.death from pancreatitis.  
Arterial 
hypertension 
SBP and/or DBP e95th percentile for sex, age, and height on e3 occasions (3 consecutive days, or separate clinic visits if outpatient). Grading: 
1.SBP/DBP in the 90th-95th percentile for age and/or BP exceeding 120/80 mmHg,  
2.recurrent or persistent SBP/DBP above 95th UNL for age at three separate measurements or lasting more than 72 hours with monotherapy indicated, 
3.recurrent or persistent SBP/DBP above 95th UNL for age at three separate measurements or lasting more than 72 hours and needing more than one drug 
or more intensive therapy than grade 2 for BP control, 
4.life-threatening consequences, e.g. hypertensive crisis with transient or permanent neurologic deficit with urgent intervention needed, 
5.death from hypertension. 
Posteror 
reversible 
encephalopathy 
syndrome  
PRES is a clinical diagnosis based on any combination of transient headache, confusion, seizures and visual disturbances in combination with 
characteristic, but transient, contrast-enhanced and DWI MRI findings (see webappendix page 9). Diagnosis can be supported by EEG findings, 
occurrence during early months of therapy, and presence of arterial hypertension. No grading.  
Seizure 
A disorder characterised by sudden, involuntary skeletal muscle contractions of cerebral/brainstem origin. Grading: 
1.brief partial seizure, 
2.brief generalised seizure,  
3.multiple seizures despite medical intervention, 
4.life-threatening, prolonged or repetitive seizures,  
5.death from seizures. 
Depressed level 
of 
consciousness 
Abnormal changes in 1) level of arousal or 2) altered content of a patient's thought processes.  
1) Quantified by Glasgow Coma Scale or the patient being alert (appear wakeful and aware of self and environment), lethargic (mild reduction in alertness), 
obtundated (moderate reduction in alertness with increased response time to stimuli), stuporous (deep sleep; arousal only by vigorous/repetitive stimulation 
and return to deep sleep when discontinued), or comatose (unconscious, sleep-like appearance and behaviorally unresponsive to all external stimuli).  
2) Can involve simple capabilities (speech, calculations, spelling) and more complex modalities (emotions, behavior or personality) with confusion, 
disorientation, hallucinations, poor comprehension, or verbal expressive difficulty.  
Methotrexate-
related, stroke-
like syndrome 
Neurotoxicity occurring within 21 days of intravenous or intrathecal MTX with three characteristics that all need to be fulfilled:  
1.new onset of one or more of paresis/paralysis; movement disorder or bilateral weakness; aphasia/dysarthria; altered mental status including 
consciousness (e.g. somnolence, confusion, disorientation, emotional lability); and/or seizures with at least one of the other symptoms, 
2.either characteristic, but often transient, white matter changes indicating leukoencephalopathy on MRI or a characteristic clinical course with waxing and 
waning symptoms usually leading to complete (sometimes partial) resolution within a week,  
3.no other identifiable cause.  
Note: Characteristic oval-shaped lesions of the subcortical white matter (mostly frontal or parietal) on MRI are best seen on diffusion-weighted 
(hyperintense) or apparent diffusion coefficient (hypointense) images. Can be graded 1-5 according to CTCAEv4.03 for “Encephalopathy”.  
Peripheral 
neuropathy 
Peripheral motor/sensory neuropathy, including pain and constipation, due to inflammation or degeneration of the peripheral motor/sensory nerves. 
Grading: 
1.loss of deep tendon reflexes, slight paresthesia, numbness or pain that do not limit instrumental ADL or require treatment,  
2.moderate symptoms somewhat limiting instrumental ADL, e.g. alters fine motor skills (ex. buttoning shirt) and/or paresthesia, numbness or pain that are 
controllable by non-narcotic medications,  
3.severe symptoms limiting self-care ADL, including gait impairment, inability to perform fine motor tasks; and/or paresthesia, numbness or pain that 
require narcotics, 
4.complete paralysis or life-threatening consequences (e.g. vocal cord paralysis) with urgent need for intervention or severe pain that is not controlled by 
narcotics,  
5.death from peripheral neuropathy (e.g. vocal cord paralysis). 
Severely 
delayed MTX 
clearance 
Increase in plasma creatinine of >0.3 mg/dl (=26.5 µM) and/or a relative increase of 1·5 above a baseline value (measured within four days prior to 
hydration preceding high-dose MTX) together with plasma MTX concentrations at one or more time-points after initiation of the MTX infusion: 36 hours 
MTX >20 µM and/or 42 hours MTX >10 µM and/or 48 hours MTX >5 µM. Renal toxicity can be graded according to CTCAEv4.03. 
Sinusoidal 
obstruction 
syndrome  
Fulfilment of at least three out of five criteria: i) hepatomegaly, ii) hyperbilirubinaemia >UNL), iii) ascites, iv) weight gain of at least 5%, and v) 
thrombocytopenia (transfusion-resistant and/or otherwise unexplained by treatment, e.g. myelosuppression). Doppler ultrasound may document changes in 
hepatic portal venous flow and rule out alternative causes, but normal findings do not exclude sinusoidal obstruction syndrome. Grading: 
1.mild: bilirubin <103 µM and weight gain <5%;  
2.moderate: bilirubin 103-342 µM and/or weight gain >5% or ascites;  
3.severe: bilirubin >342 µM and/or respiratory or renal failure or hepatic encephalopathy; 
4.death due to SOS. 
Thrombo-
embolism 
Venous and/or arterial TE. Confirmation by imaging or by autopsy is required for grade 2 and higher. Grading: 
1. superficial thrombophlebitis or CVL-associated deep venous thrombosis with neither symptoms (e.g. pain, shortness of breath) nor objective signs (e.g. 
swelling, discoloration, collaterals); or causing only CVL dysfunction. Systemic anticoagulation not given, 
2A. asymptomatic TE (including asymptomatic cerebral thrombosis). Systemic anticoagulation is usually given (not evidence-based),  
2B. symptomatic DVT, systemic anticoagulation indicated, 
3. symptomatic pulmonary embolism or cardiac mural thrombus without cardiovascular compromise or symptomatic cerebral sinovenous thrombosis or 
arterial ischaemic stroke; all grade 3 require systemic anticoagulation/antiaggregation, 
4.life-threatening TE, including arterial insufficiency, haemodynamic or neurologic instability. Urgent intervention needed, 
5.death due to TE.  
Pneumocystis 
jirovecii 
pneumonia  
1.Confirmed PJP: presence of PJ organisms# from a patient with fever, abnormal chest X-ray compatible with PJP infection, and/or hypoxaemia,  
2.Probable PJP: pneumonia of undetermined origin (fever, PJP compatible chest X-ray, and/or hypoxaemia) and responding to empiric treatment with co-
trimoxazole. 
#through cytological examination (Gomori-Grocott or Gram-Weigert staining), PJ specific PCR, or PJ immunofluorescence in a lung sample (broncho-
alveolar lavage, bronchial aspiration, transbronchial biopsy, transthoracic needle aspiration, lung biopsy, or sputum) 
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         27 toxicities considered by PTWG (see webappendix page 22, Table A1) 
AWG established for each of 14 toxicities 
Each AWG had a chair and representatives from >3 PdL ALL groups 
(subsequently expanded after each plenary PTWG meeting). Each AWG 
reviewed i) current literature with focus on ALL cohort publications, and ii) 
toxicity sections of ALL treatment protocols used by PdL groups. In between 
plenary meetings each AWG developed/refined:  
1. A definition for their toxicity 
2. A section on their toxicity for a detailed supportive PTWG document 
(webappendix). Versions of the webappendix were circulated to all PdL groups 
for comments September 2014 and March 201 
May 2015, 3rd face-to-face plenary meeting (Budapest) 
AWCs presented their findings in standardised presentations:  
1. Each toxicity definition finalised.  
2. Discussion and finalisation of 2nd draft of detailed PTWG document (webappendix). 
December 2014, 2nd face-to-face plenary meeting (San Fransisco) 
AWCs presented their findings in standardised presentations:  
1. Discussion of each toxicity definition. Focus on clarity and clinical applicability.  
2. Discussion of 1st detailed PTWG document draft (webappendix) and the comments received from PdL ALL groups.  
3. Strategies for treatment modification, toxicity capture, and registration were not discussed further, since the primary aim 
was to obtain consensus definitions. 
April 2014, 1st face-to-face plenary meeting (Prague) 
AWCs presented their findings in standardised presentations:  
1. How each ALL protocol defined and captured toxicities  
2. Emphasis on protocol diversities  
3. Implications of a toxicity for subsequent ALL therapy  
4. Weaknesses and challenges associated with current definitions  
5. Proposal for PWTG consensus definition 
13 toxicities excluded 
a. Already addressed by other groups (N=2)  
b. Too influenced by local logistics and resources (N=1)  
c. Multiple and complex causes (N=6)  
d. Already well-defined and -graded by the CTCAE with definitions 
suitable for children with ALL (N=4) 
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Webappendix to 
Consensus definitions of fourteen severe acute toxicities 
during childhood lymphoblastic leukaemia therapy 
 
This document reflects consensus statements from 15 collaborative childhood acute lymphoblastic leukaemia groups. 
Some of the statements are well supported by published data, whereas others primarily reflect the need for common 
definitions to facilitate future comparisons of incidence and severity of acute toxicities across treatment protocols and 
various dosing strategies of antileukaemic agents. The definitions will facilitate collaborative international studies for 
understanding the pathogenesis of these acute toxicities (e.g. associations with patient characteristics including 
pharmacokinetics or host genome sequence variants) and for developing guidelines for prevention, capture, diagnosis, 
registration, re-exposure and follow-up after a given toxicity.  
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Hypersensititivity to asparaginase 
Background: 
Asparaginase (Asp) plays an important role in the treatment of childhood ALL. However, efficacy can be hampered by 
anti-Asp antibodies causing clinical allergies or silent inactivation. In both conditions the Asp activity levels will be non-
therapeutic or zero (1). The hypersensitivity rate depends on the Asp preparation and the dosing, ranging from only a few 
percent in induction and up to 75% in intensification phases, when native E-coli is used in both induction and 
intensification (2,3,4,5). Contemporary protocols using pegylated (PEG)-Asp report lower hypersensitivity rates. Silent 
inactivation has been reported in 4-10% of patients (1,2,6).   
  
Current guidelines in international ALL protocols: 
Allergy (anaphylaxis and clinical allergy) is mentioned in all protocols and is graded mainly according to the United 
States National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (CTCAE) (7) in the 
majority of these. Anaphylaxis is not defined separately in most protocols, but this is probably neither a definition nor 
treatment issue. Only a few protocols have definitions of silent inactivation, and definitions differ somewhat (PEG-Asp: 
IBFM-AIEOP day 7 <100 U/l; DCOG day 7 <100 U/l and day 14 <20 U/l; DFCI 2 independent levels <25 U/l). 
Guidelines to switch preparations in case of a hypersensitivity reaction also differ across protocols. All but one protocol 
included use Peg-Asp as first-line therapy and both these and the single group using native E.coli Asp recommend switch 
to Erwinia asparaginase in case of allergic reaction or silent inactivation (if Asp activity measured). Subsequent presence 
of hypersensitivity to or inactivation of Erwinia asparaginase inactivation was addressed in three ALL protocols, of which 
one recommended substitution with one Vincristine dose and one week of glucocorticosteroids per dose of Peg-Asp 
missed, and the two others recommended different strategies of intensification of methotrexate (MTX)/6-mercaptopurine 
(6MP) maintenance therapy, and, if native E.coli Asp constituted the first-line Asp preparation, switch to Peg-Asp.  
 
Considerations before new toxicity definition: 
Discussion: All hypersensitivity reactions are important to define and register, since hypersensitivity to Asp is virtually 
always accompanied by inactivation of Asp (1). However, some patients have an ‘allergic-like reaction’ mimicking a 
clinical allergy, but without neutralisation of Asp activity. These patients might continue with the same preparation, if 
they have adequate Asp activity levels, and when it is clinically possible to administer the drug. Clinicians should be 
aware of this phenomenon. However, interpreting an Asp activity level in a blood sample taken just after a truncated 
intravenous infusion is challenging, since low levels can reflect both little Asp given prior to truncation of the infusion or 
inactivation. Anaphylaxis is included in the definition of an allergy (like in CTCAE) because the treatment modifications 
are the same.  
 
Definitions: There is consensus on the clinical signs that define hypersensitivity. Since an Asp infusion will be truncated 
during an allergy reaction, and allergies often occur at the first drops when the plasma concentration is anyway still low, 
‘inactivation of Asp activity’ is not included in the definition. In a continuous dosing schedule, a trough level 
measurement taken just before the dose leading to a hypersensitivity reaction can help distinguishing between allergy and 
allergic-like reactions. Not all groups have access to Asp activity measurements.  
 
Grading of severity: The group agrees on the grading as proposed. 
 
Consensus definition: 
Definition of allergy to Asp: 
An adverse local or general response from exposure to Asparaginase characterised by flushing, rash, urticaria, drug fever, 
dyspnoea, symptomatic bronchospasm, oedema/angiooedema, hypotension and/or anaphylaxis (accompanied by 
inactivation of Asp  activity*). 
* Trough level < LLQ before the ‘allergic’ dose. A post-infusion Asp activity level cannot be measured accurately, when 
an infusion is stopped after a few millilitres.      
 
Severity 
mild:   transient flushing or rash or drug fever < 38o C; or  
severe:  drug fever >38o C; allergy-related edema/angiooedema; dyspnoea and/or symptomatic bronchospasm  
with or without urticarial; and/or hypotension and anaphylaxis) with indication for Asp infusion 
interruption and parenteral medication (e.g. antihistamines, glucocorticosteroids). 
 
Definition of allergic-like reaction: 
An intolerance (e.g. vomiting, stomach ache, rash etc) usually occurring later in the infusion than real Asparaginase 
allergy that in general occurs at the first drops. 
Note: Distinction between hypersensitivity and allergic-like reactions is critical but may be difficult, since clinical 
hypersensitivity (even mild) is closely associated with Asparaginase inactivation. Asparaginase activity measurements 
may distinguish and guide decision on switch to other Asparaginase preparation.  
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Definition of silent inactivation: 
Patients without clinical allergy but with Asp activity levels, preferably measured in 2 independent samples, of:  
PEGasp (biweekly schedule):   Day 7 < 100 and/or day 14 < LLQ 
Erwinase (3x/week dosing schedule):  Day 2 < LLQ 
General definition:   (trough) Asp activity level < LLQ 
 
References: 
1.  Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB, van den Bos C, et al. A prospective study on drug 
monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic 
leukaemia. Blood 2014; 123: 2026-33. 
2. Schrey D, Speitel K, Lanvers-Kaminsky C, Gerss J, Moricke A, Boos J. Five-year single-center study of asparaginase 
therapy within the ALL-BFM 2000 trial. Pediatric blood & cancer. 2011 Feb 18. 
3. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, et al. Evaluation of immunologic crossreaction of 
antiasparaginase antibodies in acute lymphoblastic leukaemia (ALL) and lymphoma patients. Leukaemia. 2003; 17:1583-
8. 
4. Henriksen LT, Harila-Saari A, Ruud E, Abrahamsson J, Pruunsild K, Vaitkeviciene G, Jónsson ÓG, Schmiegelow K, 
Heyman M, Schrøder H, Albertsen BK; Nordic Society of Paediatric Haematology and Oncology (NOPHO) group. PEG-
asparaginase allergy in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Pediatr Blood 
Cancer 2015; 62:427-33.  
5. Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, 
Seibel NL, Dhall G. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic 
leukaemia: A children's oncology group report. Cancer 2015; 121: 4205-11. 
6. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, et al. Postinduction Dexamethasone and 
Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With 
Newly Diagnosed Acute Lymphoblastic Leukaemia: Results From a Randomized Study--Dana-Farber Cancer Institute 
ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31:1202-10. 
7. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. November 4th 2015 
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Hyperlipidemia 
Background:  
Asp and steroids can cause transient, and occasionally severe, hyperlipidemia with additive effect if given concomitantly 
(1-5). Data regarding incidence of hyperlipidemia are very limited, and frequency of hyperlipidemia is likely to be 
underestimated due to lack of routine measurements. Furthermore, its clinical impact with respect to associated short and 
long-term toxicities is unknown.  
 
Current guidelines in international ALL protocols:  
In spite of the frequency of hypertriglyceridemia most protocols does not address this toxicity at all, none give a clear 
definition, and only one protocol recommend routine monitoring of serum triglycerides for selected patients, but then 
only in case of a family history of hyperlipidemia. Two of three protocols with extensive Asp exposure recommend 
withholding Asp until triglycerides are below 5 times or 10 times the upper normal limit (UNL), respectively, and one of 
these in addition recommended withholding glucocorticosteroid, if triglycerides were >5x UNL and rising or if they were 
>10x UNL. 
  
CTCAE criteria:  
Grade III: > 5 – 10 times UNL (> 500 – 1000 mg/dl) 
Grade IV:  > 10 times UNL ( > 1000mg/dl) 
 
Considerations before new toxicity definition: 
The incidence of hyperlipidemia is unknown and may be underestimated as it is often self-limiting and only in rare cases 
causes severe acute toxicity. Virtually all long-term hyperlipidemia-associated toxicity reports  reflect knowledge on 
adults with non-malignant disorders. In contrast, data on long term late effects associated with hyperlipidemia in 
childhood ALL are missing. The benefits of pharmacotherapy or treatment modification to avoid or treat hyperlipidemia 
in the childhood ALL setting is unknown, and potentially may carry a risk of reducing antileukaemic treatment efficacy. 
 
Considerations before new toxicity definition: 
Due to the lack of known associations with other toxicities including long-term sequelae, there is no indication for routine 
monitoring outside a research protocol and no indication for interventions based on laboratory findings only.  
Grading of severity: The group agrees on the definitions and grading as proposed. 
 
Consensus definition:           
Triglyceride/cholesterol levels above the UNL. 
Severity: 
Mild:  Triglycerides/cholesterol <10 times UNL, 
Moderate: Triglycerides/cholesterol 10-20 times,  
Severe: Triglycerides/cholesterol > 20 times UNL. 
 
References:  
1. Parsons S et al. Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukaemia. 
Blood 1997; 89: 1886-895.  
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Osteonecrosis 
Background:  
Osteonecrosis (ON), defined as bone death resulting from poor blood supply, is a common but unclearly defined side 
effect of ALL therapy (1-18). Its reported frequency varies from less than 1% (1) to more than 70% (2). ON may cause 
significant short and long-term impairment in quality of life, as it can lead to joint articular surface collapse with 
debilitating arthritis and the potential need for surgical interventions, including arthroplasty. ON occurs in up to one third 
of adolescents and young adults with ALL. However, incidence reports have varied, perhaps given differences in whether 
reporting is based on clinical symptoms or radiological findings. While ON is most closely associated with corticosteroid 
exposure, the role of other agents, including Asp, is also being assessed. Glucocorticoids contribute to the development of 
ON by many mechanisms which include osseous lipocyte hypertrophy with resultant increased pressure within the bone 
which can lead to vascular collapse and then necrosis. Fat emboli, vasculitis or thromboemboli that cause vascular 
occlusion can also contribute and glucocorticoids can cause direct toxicity to osteocytes. Age is the strongest clinical 
predictor for ON with the highest incidence in female adolescents. 
 
Current guidelines in international ALL protocols:  
In spite of its limitations, all but one protocols used the CTCAE for clinical grading, except for one that applied the US 
Eastern Cooperative Oncology Group guidelines. Magnetic resonance imaging (MRI) is used for grading at SJCRH and 
being investigated in the current COG HR ALL study. Other groups use clinical grading systems. Treatment 
modifications for ON vary significantly:   
• Most groups recommend no modification in corticosteroid therapy for asymptomatic ON with radiographic 
findings only. 
• Some groups recommend no modification in corticosteroids during the Induction and Delayed Intensification 
phases of treatment. 
• Some groups recommend omission of steroids for Grade 2 or greater symptomatic osteonecrosis after Delayed 
Intensification with a consideration for resuming steroid therapy, if symptoms later resolve and MRI findings 
improve or normalise 
• Some groups recommend permanent discontinuation of that corticosteroids for any case of ON. 
 
Considerations before new toxicity definition: 
Definitions within protocols are largely descriptive, and most suggest confirmation by MRI. There is lack of data 
establishing the benefits of grading by MRI in addition to clinical symptoms.  While some groups screen asymptomatic 
patients for ON with MRIs, most do not. There is consensus that MRI should be applied for confirmation of clinically 
symptomatic disease rather than for screening all patients. The latter should only be used within a research project.   
 
Consensus definition:  
Osteonecrosis results from the temporary or permanent loss of the blood supply to the bones, which can cause pain, 
limitation in ADL, and may result in collapse of a articulating surface with enhanced pain and development of arthritis. It 
should be confirmed by MRI. Grading: 
1. Asymptomatic with findings only by MRI,  
2. Symptomatic, but not limiting or only slightly limiting self-care ADL. Lesions only outside joint lines in non-
weight-bearing bones, 
3. Symptomatic, but not limiting or only slightly limiting self-care ADL. Lesions in weight-bearing bones or 
affecting joint lines in non-weight-bearing bones, 
4. Symptomatic with deformation by imaging of one or more joints and/or significantly limiting self-care ADL. 
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Pancreatitis 
Background:  
Asp is an essential drug in the treatment of ALL, but has multiple side effects, including Asp associated pancreatitis 
(AAP) (1,2). AAP has a low mortality, but is one of the most frequent causes of discontinuation of Asp therapy, which 
may be associated with an increased relapse rate (3). With 6-7 months of continuous Asp therapy, the incidence of AAP 
is above 5% (1), with international reports on AAP during Asp therapy ranging 1-18% (3,6). 
 
Current guidelines in international ALL protocols: 
Most contemporary ALL protocols include definitions of AAP, although not all, and few distinguish between 
mild/moderate/severe/hemorrhagic AAP.  The CTCAE criteria, although frequently used, are not suitable for AAP 
registration and grading.  Several protocols define AAP with some modification of the Atlanta and United Kingdom 
Criteria (4,8) with at least two or three of i) Abdominal pain strongly suggestive of acute pancreatitis, ii) Serum amylase 
and/or lipase e3 (or 2) times the UNL (lipase is preferred over amylase due to greater specificity and sensitivity (7)), ii) 
Characteristic imaging findings of acute pancreatitis. The protocols varied as to whether amylase or lipase should be 
measured, whether enzymes should be e2 or 3 times UNL, and whether development of pancreatic cysts should be 
included in the definition or grading. Most protocols do not have guidelines regarding reintroduction of Asp.  
 
Considerations before new toxicity definition:  
Definition: There is consensus on following modified United Kingdom and Atlanta criteria (4,8).  
Grading of severity: There is consensus on grading as proposed below. 
 
Re-exposure: Guidelines must be adapted to the intensity of Asp treatment in the protocols, and the treatment day of 
occurrence of AAP (number of planned exposures remaining). “Asp heavy protocols” (such as DFCI) have shown 
increased relapse rate when Asp exposure is prematurely truncated (5), which has not been confirmed in less Asp 
intensive protocols (UKALL SR/IR) (6). Thus, re-exposure guidelines will be most relevant for protocols with long Asp 
exposure, but neither the risk of new episodes of AAP nor the benefits with respect to reduction of relapse rates has been 
sufficiently explored.  
 
Toxicity consensus definition: 
At least two of three features must be fulfilled: i) abdominal pain strongly suggestive of pancreatitis, ii) serum lipase or 
amylase e3 xUNL, iii) characteristic imaging findings of AAP (ultrasound, computed tomography, magnetic resonance 
imaging). Re-exposure should only be considered in mild cases. Grading: 
1. mild:  symptoms and amylase and/or lipase elevations above UNL for less than 72 hours, 
2. severe: symptoms and amylase and/or lipase elevations above UNL last more than 72 hours, or haemorrhagic 
pancreatitis or pancreatic abcess or cyst, 
3. death from pancreatitis.  
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Arterial hypertension 
This toxicity will in general be defined by national guidelines for arterial hypertension.  
 
Background: 
Hypertension in children with acute lymphoblastic leukaemia usually occurs during treatment with glucocorticosteroid 
and mostly resolves at discontinuation (1-8). Its incidence varies from 10% to 67% (2,5,6). Abnormal renal function and 
genetic polymorphisms are also considered predisposing factors (6). It can be associated with acute neurologic 
complication (Posterior reversible encephalopathy syndrome (PRES)). Some children present hypertension even after 
stopping chemotherapy; others can develop it as a late effect (isolated or part of a metabolic syndrome) (8). Hypertensive 
crisis rarely occur, and they can be symptomatic and complicated by neurological events (headache, seizures, 
haemorrhage) and require immediate intervention (aiming at reducing BP of 25% in about 8 hours).  
 
The American Association of Pediatrics staging hypertension as 
Prehypertension 90th to <95th or if BP exceeds 120/80 mmHg  
Stage 1  95th percentile to the 99th percentile plus 5 mmHg 
Stage 2  >99th percentile plus 5 mmHg 
Note: cuff size should be appropriate to the child's arm. 
 
Consensus definition: 
Hypertension is defined as average SBP and/or DBP that is greater than or equal to the 95th percentile for sex, age, and 
height on three or more occasions  (3 consecutive days, or separate clinic visits if outpatient). 
 
Grading: 
1. SBP/DBP in the 90th-95th percentile for age and/or BP exceeding 120/80 mmHg,  
2. recurrent or persistent SBP/DBP above 95th UNL for age at three separate measurements or lasting more than 72 
hours with monotherapy indicated, 
3. recurrent or persistent SBP/DBP above 95th UNL for age at three separate measurements or lasting more than 72 
hours and needing more than one drug or more intensive therapy than grade 2 for BP control, 
4. life-threatening consequences, e.g. hypertensive crisis with transient or permanent neurologic deficit with urgent 
intervention needed,  
5. death from hypertension. 
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Posterior reversible encephalopathy syndrome (PRES) 
Background: 
PRES, also named ‘reversible posterior leukoencephalopathy syndrome, is a clinico-radiological entity based on 
disturbances of cerebro-vascular autoregulation and clinically characterised by headache, confusion (altered mental 
status), seizures and visual disturbances (1-5). In pediatrics, PRES is most commonly seen in pediatric hemato-oncology 
patients. Large cohort studies on its frequency are missing. In ALL patients, PRES occurs most commonly during 
induction or during the first 3-4 months of therapy. It may occur due to a number of causes, predominantly arterial 
hypertension, chemotherapy, and immunosuppression. On cranial MRI, areas of vasogenic edema (swelling) are 
predominantly seen, but not restricted to the posterior regions of the brain, and predominantly, but not exclusively, 
bilaterally. PRES is hypointense on T1-weighted and hyperintense on T2-weighted MRI revealing both patchy and 
confluent cortical and subcortical white matter lesions most commonly in parietal and occipital lobes or cerebellum and 
less commonly in basal ganglia, brainstem, and frontal lobes.  In contrast to MTX-associated stroke-like syndrome, PRES 
is hyperintense on apparent diffusion weighted coefficient MRI images (DWI). EEGs usually show non-specific 
alterations sometimes with epileptiform discharges in posterior brain regions.  
 
Current guidelines in international ALL protocols: 
Detailed description and definition of PRES is only provided within the NOPHO protocol (adapted CTCAE).  
 
Consensus definition:  
Diagnosis of PRES is based on the essential and additional criteria below, but with no grading. 
Essential criteria:  
1) Clinical findings: any combination of headache, confusion, seizures and visual disturbances 
2) Imaging findings: best imaging tool: contrast-enhanced MRI and DWI 
– Best diagnostic clue: patchy (and confluent) cortical (and subcortical) territory lesions 
– Most common location: cortex, subcortical white matter 
– Predilection: parietal and occipital lobes, cerebellum; less common: basal ganglia, brainstem, frontal lobes 
– Size: extent of abnormalities highly variable 
– Mass effect: minimal or none  
– Enhancement: minimal or none 
– MRI findings: 
          T1WI: hypointense cortical / subcortical lesions 
          T2WI: hyperintense cortical / subcortical lesions 
On DWI images PRES is ususally normal or hyperintense. 
 
Additional supportive findings: 
1) Timing: usually during the first 3-4 months of therapy (mostly during remission induction therapy) 
2) Presence of arterial hypertension 
3) Complete resolution of clinical/imaging findings, although MR findings may persist in some patients 
4) EEG: usually non-specific alterations, sometimes epileptiform discharges in the posterior region of the brain may be 
visible  
5) Other causes reasonably ruled out 
 
Treatment modifications:  
As the pathophysiology of PRES is not clearly elucidated and PRES represents a multifactorial entity, recommendations 
concerning treatment modifications is difficult to establish beyond the already existing guidelines that include postponing 
intrathecals until almost complete normalisation of the MRI findings, freedom of clinical epilepsy and improvement of 
EEG abnormalities, and administration of anti-convulsant therapy (avoiding those inducing hepatic microsomal enzymes) 
and anti-hypertensive therapy. 
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Seizures 
Background:  
Seizures are the commonest form of acute neurotoxicity during treatment for leukaemia and may be seen in up to 10% of 
children during treatment (1,2). Published data are limited, but a large series of 62 children with ALL or NHL from St 
Jude Children’s Research Hospital (SJCRH) describes the characteristic features. Risk factors appear to be female sex and 
age <3 years (3). Seizures have a diverse aetiology - up to 60% are related to chemotherapy toxicity (predominantly MTX 
- either as part of a stroke-like syndrome (MTX-SLS) or occurring in isolation) with 10% due to intracranial 
haemorrhage, 8% to cerebral venous sinus thrombosis (CVST), 6% due to CNS infections and 16% unknown (3). Other 
reported causes include PRES, hyperviscosity and electrolyte imbalance. The first seizure can be complex partial (60%) 
or generalised tonic-clonic (40%). 25% occur in the first 6 weeks after diagnosis with 75% occurring within 18 months. 
In the SJCRH series 44/62 patients had controlled seizures and 18/62 uncontrolled at the last follow-up (3).  
 
Current guidelines in international ALL protocols:  
Most contemporary ALL protocols describe neurotoxicity and/or seizures as a potential side effect of MTX and/or 
ifosfamide, vincristine and cytarabine therapy. Grading is generally according to CTCAE: Grade 1 - brief partial seizure, 
Grade 2 - brief generalised seizure, Grade 3 - multiple seizures despite medical intervention, Grade 4 - life-threatening 
prolonged repetitive seizures, Grade 5 – death. Some protocols (e.g. DFCI 11-001) list seizures as an expected AE that 
does not require reporting (unless life-threatening), whilst others (e.g. AIEOP-BFM 2009) list all seizures as mandatory 
reportable AEs. Many protocols request all grade 2-4 events to be reported. Some protocols state that re-exposure is safe 
after MTX-related seizure, if full neurological recovery has occurred. In BFM-AIEOP 2009, ifosfamide-related seizures 
indicate discontinuation of that drug and replacement with cyclophosphamide.   
 
Considerations before new toxicity definition: 
Discussion: Since seizures can occur in isolation or as part of another recognized toxicity (CNS thromboembolism, 
PRES, MTX-SLS etc) they may be particularly prone to dual reporting or under-reporting. Since seizures are common 
they may be an important early indicator of increased neurotoxicity with new protocols/therapeutic agents and therefore 
this information should be captured, when possible and irrespective of grading.  
Definitions: CTCAE defines a seizure as a disorder characterised by sudden, involuntary skeletal muscle contractions of 
cerebral or brainstem origin. This definition excludes absence seizures. An alternative definition comes from the the 
International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) who define a seizure as a 
transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain 
(4). Both definitions have advantages and disadvantages. Since absence seizures are not typically seen during ALL 
therapy the CTCAE definition may be preferable, as it does not rely on having EEG evidence of seizure activity. 
Grading of severity: Under CTCAE brief partial or generalized seizures are grade 1 and 2 respectively and therefore these 
would not be routinely reported in many ALL protocols, since they restrict reporting to Grade 2-5 or 3-5 events only.   
 
Consensus definition: 
Seizures are defined as a disorder characterised by sudden, involuntary skeletal muscle contractions of cerebral or 
brainstem origin. They are sub-classified according to partial vs. generalised and duration/response to therapy.  
Severity: Grade 1 - brief partial seizure, Grade 2 - brief generalised seizure, Grade 3 - multiple seizures despite medical 
intervention, Grade 4 - life-threatening, prolonged or repetitive seizures, Grade 5 – death from seizures. 
 
References:  
1. Mahoney DH, Jr., Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid 
leukaemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric 
Oncology Group study. J Clin Oncol 1998;16:1712-22. 
2. Ochs JJ, Bowman WP, Pui CH, Abromowitch M, Mason C, Simone JV. Seizures in childhood lymphoblastic 
leukaemia patients. Lancet 1984;2:1422-4. 
3. Khan RB, Morris EB, Pui CH, et al. Long-Term Outcome and Risk Factors for Uncontrolled Seizures After a First 
Seizure in Children With Hematological Malignancies. J Child Neurol 2013;29:774-781. 
4. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the 
International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470-
472. 
  
11 
 
Depressed level of consciousness 
Background:  
Decreased consciousness including coma has multiple aetiologies such as sepsis, electrolyte imbalance, vascular or 
neurologic events and direct toxic effects of chemotherapeutic agents (1-11). A decreased level of consciousness is more 
often described than coma. The frequency of depressed consciousness in various ALL protocols have not been 
determined, but the frequency of coma varies from 1% (10) to 4% (11), and it constitute between 5% (10) to 50% (11) of 
all registered neurotoxic events. 
Aetiologies for coma/decreased consciousness in children and adolescents with ALL include: 
1. Sepsis. 
2. Encephalitis: viral, bacterial, fungal. 
3. Progressive multifocal leukoencephalopathy. 
4. Chemotherapy induced (1, 2, 5, 8, 6, 9, 13): 
• Cyclophosphamide, Fludarabine, Ifosfamide, cytarabine, Asp, MTX, Vincristine.   
• Cranial radiation. 
5. Intracranial haemorrhage /thrombosis. 
6. Posterior reversible encephalopathy syndrome. 
7. Hypertensive encephalopathy. 
8. IT MTX; acute and subacute leukoencephalopathy. 
9. Accidental intrathecal Vincristine (6). 
10. Electrolyte disturbance. 
11. Direct effects of leukaemia on the nervous system.  
12. Indirect effects of leukaemia on the nervous system:  stroke or haemorrhage from hyperviscosity syndromes (7). 
13. Hyperamoneamic encephalopathy (13). 
14. Hyperglycemic-hyperosmolar non ketotic syndrome after therapy with prednisone or Asp (4). 
15. Narcotic withdrawal. 
16. Drug use/abuse. 
17. Hepatic failure. 
18. Hypothermia. 
 
Current guidelines in international ALL protocols: 
There is no reference to coma in any of the protocols, but most protocols address encephalopathy and decreased 
consciousness as one toxicity. Many protocols use the CTCAE classification, which defines “depressed level of 
consciousness” as: 
A disorder characterised by decreased ability to perceive and respond. 
Grade 1: Decreased level of alertness.  
Grade 2: Sedation; slow response to stimuli; limiting instrumental ADL. 
Grade 3: Difficult to arouse.  
Grade 4: Life-threatening consequences.  
Grade 5: Death. 
 
Considerations before new toxicity definition:  
There is no common definition of coma/depressed level of consciousness, or recommendation for evaluation, therapy and 
further exposure to the chemotherapy agent in any of the contemporary ALL protocols. Grading of the severity of the 
depressed level of consciousness seem be more appropriate than a simple classification of coma. Any re-exposure to 
potential toxic antileukaemic agents must include consideration of aetiology, concomitant drugs administered, 
chemotherapy given and planned, and the patients current medical condition. 
 
Consensus definition:  
Abnormal change in level of arousal or altered content of a patient's thought processes (12). The level of arousal is 
assessed by the Glasgow Coma Scale (GCS) where coma is classified GCS 3-8, moderate depression of consciousness as 
GCS 9-12, and minor depression of consciousness as GCS 13-15. An alert (conscious) patient has the appearance of 
wakefulness and awareness of self and environment. 
Change in the level of arousal or alertness:  
Grade A1: Lethargy - mild reduction in alertness  
Grade A2: Obtundation - moderate reduction in alertness. Increased response time to stimuli.  
Grade A3: Stupor - Deep sleep, patient can be aroused only by vigorous and repetitive stimulation. Returns to deep sleep 
when not continuously stimulated.  
Grade A4: Coma (Unconscious) – Sleep-like appearance and behaviorally unresponsive to all external stimuli 
(Unarousable unresponsiveness, eyes closed). 
Change in content (thought processes):  
Grade B1: “Relatively simple” changes: e.g. speech, calculations, spelling.  
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Grade B2: More complex changes: emotions, behavior or personality, e.g. confusion, disorientation, hallucinations, poor 
comprehension, or verbal expression.  
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Stroke-like Syndrome (SLS), Methotrexate-related 
Background:  
MTX is associated with a wide range of neurotoxicities including seizures, headaches and altered mental status. Amongst 
these a “stroke-like syndrome” (SLS) (also known as subacute MTX-related encephalopathy) is a well described, but 
poorly understood,  entity. This typically includes focal neurological deficits or hemiparesis, often accompanied by 
disturbances in speech and/or affect, which can wax and wane over the course of hours to days. This subacute MTX-
related encephalopathy develops within three weeks (usually between 2 and 14 days) after MTX administration and in 
most cases resolves completely over a few days. The incidence of SLS varies from <1%-15% in the literature (1-5) and 
appears to vary according to the scheduling and intensity of MTX and co-administration of other agents such as 
cyclophosphamide and Ara-C. It also appears to be commoner in children aged >10 years. Although most patients make a 
full recovery, there are also reports of persisting neurological deficits in some cases (2). MTX interferes with potentially 
neurotoxic amino acid and neurotransmitter pathways causing accumulation of homocysteine and its metabolites with 
strong excitatory effect on the N-methyl-D-aspartate receptor (NMDAR). These changes can be reversed by 
dextromethorphan, a non-competitive antagonist to NMDAR. Use of Dextromethorphan a non-competitive antagonist to 
NMDAR or aminophylline (more relevant for acute MTX-induced neurotoxicity) have both been advocated in small case 
series (6,7). However, the unknown pathophysiology of SLS, the transient nature of the symptoms, and rapid resolution in 
many patients without active treatment, make it difficult to assess the impact of these interventions. Further research is 
needed. 
 
Current guidelines in international ALL protocols: 
Most contemporary ALL protocols describe SLS and/or neurotoxicity as a potential side effect of MTX. However, formal 
definitions are not included in most trial protocols. Although neurotoxicity grading can be via CTCAE criteria, CTCAE 
does not list SLS as an adverse event. Thus, SLS could be classified as “Leukoencephalopathy”, “Encephalopathy”, 
“Stroke” or “Nervous system disorders – other”. Most protocols state that re-exposure to MTX can be attempted (or 
discussed with trial coordinators) once the neurotoxicity resolves, although there are modifications in some protocols 
depending on whether or not toxicity occurred during high-dose MTX blocks.  
 
Considerations before new toxicity definition: 
SLS is a discrete entity which is clinically well characterised. However some overlap in symptoms may occur with PRES 
and radiological criteria for distinguishing between the two syndromes are not clearly defined. Recent DWI data suggest 
that the two syndromes may be distinguished by opposing effects on measured apparent diffusion co-efficient (ADC) 
values with PRES having increased values (due to vasogenic oedema) (3) and SLS reduced ADC values (due to cytotoxic 
oedema) (4,5), but this needs confirming in larger studies. Although seizures are a common feature of SLS, they can also 
occur without the rest of the SLS syndrome and may or may not have the same pathophysiology. Therefore, although 
seizures are listed amongst the neurological symptoms, an isolated seizure would not fulfill the diagnostic criteria for 
SLS.  
Grading of severity: CTCAE grading is not particularly clinically useful and the subheading under which to record the 
toxicity is not clear. Some radiological criteria exist for leukoencephalopathy but their relevance in the SLS context is not 
established. Identifying predictors of a severe course or incomplete recovery is an important area for future research. 
 
Consensus definition: 
Patients must fulfil all 3 of the following criteria:  
1. New onset of one or more of the following neurological symptoms/signs within 21 days of MTX therapy (intrathecal 
or intravenous):  
• Paresis/paralysis  
• Aphasia/dysarthria 
• Altered mental status- somnolence, confusion, disorientation, emotionally lability etc  
• Movement disorder 
• Loss of consciousness 
• Bilateral weakness 
• Seizures (isolated seizures without accompanying features from the list above and without criteria 2 and 3 below 
are excluded) 
2. EITHER:  Findings of characteristic white matter changes of leukoencephalopathy on MRI (see below)  
       AND/OR:  Characteristic clinical course with waxing and waning symptoms usually leading to complete resolution 
over 1-7 days  (Note in severe cases only partial resolution may be seen in this time frame) 
Characteristic MRI findings (best seen on T2-weighted images or ideally with DWI) include: oval shaped lesions of the 
subcortical white matter, often in the frontal, or parietal areas and often not conforming to a vascular territory. Lesions are 
generally hyperintense on DWI and hypointense on ADC. 
3. No other identifiable cause. 
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Note that these changes (including DWI) may be transient and therefore missed if the scan is delayed for a few days after 
onset of symptoms, however subtle T2 and Fluid attenuation inversion recovery (FLAIR) abnormalities may remain in 
some cases. 
Severity grading: CTCAE should continue to be used and all SLS recorded under “Encephalopathy” and graded 1-5. 
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Peripheral neuropathy 
Background:  
Peripheral motor and/or sensory neuropathy is common and generally caused by vincristine and in that case nearly always 
reversible (1). This toxicity is addressed by all treatment protocols with the CTCAE grading, except for one group 
applying the Balis scale (1). Paralysis is considered as the most severe form of “peripheral neuropathy” or “paresthesias”, 
mainly induced by vincristine or neralabine. There is no clear definition/grading system about paralysis due to CNS 
events. Paralysis during ALL treatment is common, but generally reversible, and has a low direct morality, although it 
may require many months for improvement and no effective medical treatment for paralysis. There is limited reporting 
regarding incidence of paralysis associated with ALL treatment. In recent reports, the incidence of grade 2-4 (CTCAE) 
vincristine-induced neuropathy was vary widely (2,3). 
 
Current guidelines in international ALL protocols:  
CTCAE criteria defines peripheral motor/sensory neuropathy in nervous system disorders as a disorder characterised by 
inflammation or degeneration of the peripheral motor/sensory nerves. Paresthesia, a symptom of sensory neuropathy, is 
defined as a disorder characterised by functional disturbances of sensory neurons resulting in abnormal cutaneous 
sensations of tingling, numbness, pressure, cold, and warmth that are experienced in the absence of a stimulus. 
In COG protocol, BALIS pediatric scale of peripheral neuropathy is used for grading. Some protocols include 
constipation as peripheral neuropathy. Vocal cord paralysis was defined as severe neuropathy in a few protocols. In most 
protocols, there is no clear definition of paralysis due to CNS events. Most protocols do not have criteria for dose 
reduction of VCR because of paralysis, since it is generally reversible without life threatening event, except vocal cord 
paralysis. In a few protocols, dose reduction for paresthesis or motor paralysis is defined (DFCI, St. Jude). 
  
Considerations before new toxicity definition:  
Definition: The motor and sensory definition should be evaluated separately.  
Grading of severity: Combine the BALIS scale (used in COG protocols) and CTCAE. 
Re-exposure: Re-exposure is usually permitted if symptoms are improved. 
 
Toxicity consensus definition:  
Peripheral motor or sensory neuropathy (can include pain and constipation) due to inflammation or degeneration of the 
peripheral motor/sensory nerves. Grading: 
1. loss of deep tendon reflexes, slight paresthesia, numbness or pain that do not limit instrumental ADL or require 
treatment,  
2. moderate symptoms somewhat limiting instrumental ADL, e.g. alters fine motor skills (ex. buttoning shirt) 
and/or paresthesia, numbness or pain that are controlled by non-narcotic medications,  
3. severe symptoms limiting self-care ADL, including gait impairment, inability to perform fine motor tasks; 
and/or paresthesia, numbness or pain that require narcotics, 
4. complete paralysis or life-threatening consequences (e.g. vocal cord paralysis) with urgent need for intervention 
or severe pain that is not controlled by narcotics,  
5. death from peripheral neuropathy (e.g. vocal cord paralysis). 
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Severely delayed methotrexate clearance with renal toxicity  
Background:  
Although the use of alkalinisation and hydration with high-dose MTX (HDMTX) significantly reduces the risk for renal 
toxicity, approximately 2% of patients treated with HDMTX develop renal toxicity that compromises MTX clearance and 
results in excessive exposure (1;2). Plasma creatinine usually peaks within four days after initiation of the HDMTX 
infusion and returns to baseline after a few weeks (3). Higher doses of folinic acid are essential to limit toxicity in 
situations with excessive MTX exposure. In rare cases (<0.5% of all 5 g/m² HDMTX infusions) carboxypeptidase may be 
‘helpful’ to degrade plasma MTX rapidly by enzymatic cleavage – independently of renal function (1;3). 
Caboxypeptidase has no immediate effect on MTX in the renal tubules that may be impeding renal function. Despite the 
availability of carboxypeptidase, diuresis and folinic acid rescue remain the mainstay of high dose MTX therapy. Even 
lower systemic MTX exposure can cause severe toxicity, if folinic acid is delayed more than 42 to 48 hours after 
initiation of the infusion (4-7). No prospective randomised studies have compared different folinic acid doses and 
schedules. However, several investigators suggest that excessive folinic acid may rescue the leukaemia cells and increase 
the risk of relapse. The assertion of this remains controversial (8;9).  
 
Current guidelines in international ALL protocols:  
Most ALL protocols using HDMTX 2.5-5 g/m² have guidelines that define the following plasma MTX concentrations as 
severely high and some suggest that carboxypeptidase may be used in such cases if available:  
 
 Plasma MTX conc. ALL Protocol 
24h MTX > 250 µM NOPHO 
36h MTX > 10-20 µM BFM-AIEOP, NOPHO, 
UKALL  
42h MTX > 5-10 µM NOPHO, COG, St Jude, 
TPOG  
48h MTX > 3-10 µM COG, DCOG, UKALL 
 
In protocols from BFM-AIEOP, DFCI, EORCT and Israel, no specific guidance is offered with regard to use of 
carboxypeptidase.   
 
Considerations before new toxicity definition:  
Patients with very high plasma MTX concentrations usually also have renal toxicity with increased serum creatinine. Few 
patients have an increase of more than 1.5-2.0-fold from baseline (1,10,11). The CTCAE defines renal toxicity as an 
increase in creatinine by > 0.3 mg/dl or a relative increase of 1.5-fold above baseline (12). In most ALL protocols the 
folinic acid dose is increased if plasma MTX is >1uM 42 hours after initiation of the HDMTX infusion because 
concentrations above this level are associated with increased toxicity (13-15). When the plasma MTX concentration is > 
10 uM at 42-hour then the folinic acid dose has to be increased markedly to achieve a plasma tetrahydrofolate 
concentration of 1000 uM which is believed required to prevent serious toxicity (5;15).  
 
Consensus definition: 
An increase in plasma creatinine by >0.3 mg/dl or a relative increase of 1.5 above baseline together with severely high 
plasma MTX concentrations at one or more of the following time-points after initiation of the MTX infusion, independent 
of the MTX dose: 36h MTX >20 µM and/or 42h MTX >10 µM and/or 48h MTX >5 µM. The baseline plasma creatinine 
should be measured within four days prior to start of the hydration preceding the HDMTX infusion and be monitored 
until sufficient MTX clearance is confirmed.  
        Criteria for use of carboxypeptidase is not included in the consensus criteria (1,3,16). 
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Sinusoidal obstruction syndrome (SOS) 
Background: 
Sinusoidal obstruction syndrome (SOS) also called veno-occlusive disease (VOD) is a well documented toxicity of 6-
thioguanine (6TG), occurring in 206 (20%) of 1017 patients randomised to 6TG in the COG CCG-1952 trial, and in 82 
(11%) of 748 randomised to 6TG in the ALL97 trial (1,2). However, rates of SOS may be influenced by scheduling and 
concomitant medication. In the CoALL92 trial no SOS was seen in either the 6-TG or 6MP arms (3). VOD appears to be 
very unusual during 6MP treatment (no cases occurred during 6MP treatment in CCG-1952 or UKALL97). Most ALL 
treatment trials and protocols have now replaced 6TG with 6MP. Most patients with mild 6TG-induced SOS tolerate the 
subsequent introduction of 6MP without suffering any further problems (4). Additive hepatotoxicity from Asp and MTX 
may be an important factor. 
 
Current guidelines in international ALL protocols: (A summary from international ALL protocols) 
Only two contemporary ALL protocols mention SOS/VOD at all, and only one of these includes a definition of VOD. 
NOPHO ALL 2008 defines veno-occlusive disease or SOS of the liver as painful hepatomegaly, ascites, weight gain 
>5%, thrombocytopenia, and retrograde portal venous flow. AIEOP-BFM ALL 2009 warns that patients with one variant 
TPMT allele (heterozygous genotype) are at a strongly elevated risk of developing hepatic VOD when exposed to 6TG. It 
states that “potential signs of VOD should be closely monitored in protocol IIB or protocol IIIB, particularly in patients 
with TPMT heterozygosity, in order to allow appropriate diagnostic and therapeutic measures to be introduced in a timely 
manner”, but neither this trial, nor any others, makes any recommendations on when to modify or stop 6TG treatment. 
There is no specific definition of SOS/VOD in the CTCAE. 
 
Consideration before new toxicity definition: 
ALL protocols have now replaced 6TG with 6MP. Most patients with mild 6TG-induced SOS tolerate the subsequent 
introduction of 6MP without suffering any further problems (4).   
 
Toxicity consensus definition: 
Sinusoidal obstruction syndrome: 
Fulfillment of at least three out of five criteria: 
1. Hepatomegaly,  
2. Hyperbilirubinaemia,  
3. Ascites,  
4. Weight gain >5%, and  
5. Thrombocytopenia, otherwise unexplained and transfusion-resistant. 
 
Doppler ultrasound may document changes in hepatic portal venous flow and rule out alternative causes, but normal 
Doppler findings do not exclude a diagnosis of VOD.  
 
Grading: 
Mild: Bilirubin <103 µM and weight gain <5%. 
Moderate: Bilirubin 103-342 µM and either weight gain >5% or ascites. 
Severe: Bilirubin >342 µM and respiratory or renal failure or hepatic encephalopathy. 
 
Treatment Modifications: 
If SOS  fulfilling the above criteria occurs, hepatotoxic treatment (6MP/6TG, Asp, MTX etc) should be withheld until 
SOS has resolved. If SOS has occurred whilst the patient was taking 6TG, it may be possible to start 6MP as a substitute 
for 6TG, if the clinical features of SOS resolve.  
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Arterial and venous thromboembolism (TE) 
Background: 
The incidence of TE in childhood ALL ranges between 2% (1) and 37% (2) with an overall average of symptomatic TE 
of 5% (3-5). This diversity in part reflects differences in definitions. TE is mostly located in the venous system as cerebral 
sinovenous thrombosis (CSVT) or central vein line (CVL)-associated deep venous thrombosis (DVT). Contributing 
factors to TE in ALL patients include administration of Asp and steroids, presence of CVL, inherited or acquired 
thrombophilia, infection, and possible other factors such as hyperlipidaemia (3,2,6,7). Older patients are more susceptible 
to TE (3). Mortality directly related to venous TE (VTE) in children is 2-9% (6,8,9). VTE impacts on the scheduled Asp 
treatment and may accordingly have negative influence on overall survival outcome in children with ALL. 
 
Current guidelines in international ALL protocols: 
Venous and/or arterial TE is graded according to CTCAE in the majority of treatment protocols. TE of CTCAE Grade e3 
is generally registered and only symptomatic TE considered clinically significant in the most of treatment protocols. TE 
definition is not specified in many of the treatment protocols.  
 
Considerations before new toxicity definition and grading: 
There is an agreement on the need to confirm TE by imaging, when TE is defined as a toxicity. The ad hoc working group 
(AWG) members agree to define Grade 1 as CVL-associated DVT without any symptoms (e.g., pain, shortness of breath, 
etc) or objective signs (e.g. swelling, discoloration, collaterals, etc) or causing only CVL dysfunction where no systemic 
anticoagulation is given or only endoluminal instillation of fibrinolytics is indicated. We propose do not register the 
Grade 1 as toxicity. 
Difficulties in grading include different management of asymptomatic TE. Most members use systemic anticoagulation in 
asymptomatic TE, but some do not. Thus, asymptomatic and symptomatic TE should be graded separately (Grades 2A 
and 2B).  
The proposed grading differs from CTCAE grading as we suggest asymptomatic (incidentally diagnosed) TE to be 
defined as Grade 2 vs. Grade 1 in CTCAE and cerebrovascular thrombosis as Grade 3 vs. Grade 4 in CTCAE. 
 
Consensus definition:  
Venous and/or arterial thromboembolism (TE). Confirmation by imaging or by autopsy is required by grade e2. 
Grading: 
1. superficial thrombophlebitis or CVL-associated DVT without symptoms or objective signs or causing only CVL 
dysfunction. Systemic anticoagulation not given; 
2. A. asymptomatic TE (including asymptomatic cerebral thrombosis). Systemic anticoagulation is usually given 
(not evidence-based); 
B. symptomatic DVT, systemic anticoagulation indicated;  
3. symptomatic pulmonary embolism or cardiac mural thrombus without cardiovascular compromise or 
symptomatic cerebral sinovenous thrombosis or arterial ischaemic stroke; all grade 3 require systemic 
anticoagulation/antiaggregation; 
4. life-threatening TE, including those with arterial insufficiency, hemodynamic or neurologic instability. Urgent 
intervention needed; 
5. death due to TE.  
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Pneumocystis jiroveci Pneumonia 
Background:  
Pneumocystis Carinii, more recently reclassified as Pneumocystis Jiroveci (PJP), is a fungus commongly found in the 
environment.  Whilst it rarely causes illness in healthy individuals, it may cause life-threatening or fatal pneumonia in the 
immunocompromised host, including patients with ALL (1-3).  The definition of PJP infection, the prophylaxis regimen 
and treatment schedules vary across different international groups and support the development of a common definition 
and therapeutic strategy. 
 
Current guidelines in international ALL protocols: 
PJP is graded mainly according to CTCAE in the majority of the treatment protocols.  There are no specific diagnostic 
criteria defined for PJP infection in ALL protocols.  Patients receiving chemotherapy for ALL routinely receive 
prophylaxis against PJP with Co-trimoxazole, although the dose and schedule for Co-trimoxazole  administration is 
variable across international study groups. Treatment for presumed PJP is generally with high dose Co-trimoxazole, 
however other agents are sometimes used by some centres in patients with severe cytopenias. 
 
Considerations before new toxicity definition:  
There are no specific definitions for PJP infection in international ALL protocols.  The Infectious Disease Working 
Group of the EBMT have published definition of PJP in the context of haemopoietic stem cell transplantation.  There are 
no definitions published by the HIV community. We favour a modified version of the EBMT definitions in which PJP is 
either unequivocally confirmed or deemed likely by clinical features.   
 
Toxicity consensus definition:  
Confirmed PJP infection: Presence of Pneumocystis Jiroveci (carinii) organisms identified through cytological 
examination (Gomori-Grocott or Gram-Weigert staining), PCR or immunofluorescence in a lung sample (broncho-
alveolar lavage, bronchial aspiration, transbronchial biopsy, transthoracic needle aspiration, lung biopsy, or sputum) in a 
patient with fever or abnormal chest X-ray, or hypoxemia. 
Probable PJP infection: Patients with pneumonia of undetermined origin (with fever and abnormal chest X-ray and/or 
hypoxemia compatible with PJP) and responding to empiric treatment with Co-trimoxazole. 
 
References:  
1. Castagnola E, Zarri D, Caprino D, Losurdo G, Micalizzi C. Cotrimoxazole prophylaxis of Pneumocystis carinii 
infection during the treatment of childhood acute lymphoblastic leukaemia--beware non compliance in older children 
and adolescents. Support Care Cancer 2001; 9:552-3. 
2. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, 
Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini 
G, Cappucci MA, Russo D, Corvatta L, Martino P, Del Favero A. Pneumocystis carinii pneumonia in patients with 
malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 
117:379-86. 
3. Levinsen M, Shabaneh D, Bohnstedt C, Harila-Saari A, Jonsson OG, Kanerva J, Lindblom A, Lund B, Andersen 
EW, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Pneumocystis jiroveci 
pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-
free survival for childhood acute lymphoblastic leukaemia. Eur J Haematol 2012;88:78-86.  
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Table A1. Childhood acute lymphoblastic leukaemia acute toxicities considered by the Ponte di Legno Toxicity Working Group (PTWG); outcome; and key members in the 
working committees for the toxicities reaching consensus definitions. 
Toxicity Results Members (ALL group) in each ad hoc working committee 
Hypersensitivity to asparaginase Consensus definition by PTWG 
Andishe Attarbaschi (BFM-Austria), Anja Möricke (BFM-Germany), Gabriele Escherich (COALL), Elizabeth Raetz (COG), 
Inge van der Sluis (DCOG, chair),  Veerle Mondelaers (EORTC), Motohiro Kato (Japan), Birgitte Klug Albertsen (NOPHO), 
Hiroto Inaba (SJCRH), Der-Cherng Liang (TPOG), Jayashree Motwani (UKALL). 
Hyperlipidemia Consensus definition by PTWG 
Deepa Bhojwani (SJCRH), Der-Cherng Liang (TPOG), Mike Gattens (UKALL), Inge van der Sluis (DCOG), Ester Zapotocka 
(Czech republic), Thomas Frandsen (NOPHO), Gabriele Escherich (COALL, chair). 
Osteonecrosis Consensus definition by PTWG 
Andishe Attarbaschi (BFM-Austria), Arndt Borkhardt (BFM), Gabriele Escherich (COALL), Caroline Piette (EORTC), Riitta 
Niinimäki (NOPHO), Frederik Van Delft (UKALL), Rachael Hough (UKALL), Sima Jeha (SJCRH), Der-Cherng Liang 
(TPOG), Elizabeth Raetz (Chair). 
Asparaginase-associated pancreatitis Consensus definition by PTWG 
Thomas Frandsen (NOPHO, chair), Motohiro Kato (Japan), Sima Jeha (SJCHR), Der-Cherng Liang (TPOG), Sujith 
Samarasinghe (UKALL), ), Inge van der Sluis (DCOG), Elizabeth Raetz (COG), Ester Zapotocka(Czech Republic). 
Arterial hypertension Consensus definition by PTWG Maria Caterina Putti (AIEOP, Chair), all groups contributed. 
Posteror reversible encephalopathy syndrome  Consensus definition by PTWG 
Andishe Attarbaschi (BFM-Austria), Inge van der Sluis (DCOG), Der-Cherng Liang (TPOG), Anja Möricke (BFM-Germany), 
Shlomit Barzilai (INS), Arja Harila-Saari (NOPHO), Bhojwani Deepa (SJCRH) 
Seizure 
Consensus definition by PTWG Andishe Attarbaschi (BFM-Austria), Anja Möricke (BFM-Germany), Shlomit Barzilai (INS),  Deepa Bhojwani (SJCRH), 
Motohiro Kato (Japan), Der-Cherng Liang (TPOG), Christina Halsey (UKALL, WG chair). 
Depressed level of consciousness Consensus definition by PTWG 
Andishe Attarbaschi (BFM-Austria), Anja Moricke (BFM), Deepa Bhojwani (SJCRH), Hsi-Che Liu (TPOG), Shlomit Barzilai 
(INS, chair). 
Methotrexate-related stroke-like syndrome Consensus definition by PTWG 
Christina Halsey (UKALL, WG chair), Andishe Attarbaschi (BFM-Austria),  Anja Möricke (BFM-Germany), Gabriele 
Escherich (COALL), Paul Gaynon (COG), Inge van der Sluis (DCOG), Shlomit Barzilai (INS), Kjeld Schmiegelow (NOPHO),  
Deepa Bhojwani (SJCRH), Der-Cherng Liang (TPOG). 
Peripheral neuropathy Consensus definition by PTWG 
Andishe Attarbaschi (Austria), Anja Möricke (BFM), Der-Cherng Liang (TPOG), Sujith Samarasinghe (UK), Hiroto Inaba 
(SJCRH), Motohiro Kato (Japan). 
High-dose methotrexate related nephrotoxicity Consensus definition by PTWG Torben Stamm Mikkelsen (NOPHO, WG chair), Paul Gaynon (COG), Deepa Bhojwani (SJCHR/COG). 
Sinusoidal obstruction syndrome  Consensus definition by PTWG 
Christina Halsey (UKALL) (WG co-chair), Rod Skinner (UKALL) (WG co-chair), Andishe Attarbaschi (BFM-Austria), 
Gabriele Escherich (COALL),  Thomas Frandsen (NOPHO), Der-Cherng Liang (TPOG), Anja Möricke (BFM-Germany), Inge 
van der Sluis (DCOG). 
Thromboembolism Consensus definition by PTWG 
Ruta Tuckuviene (NOPHO, WG chair), Maria Caterina Putti (AIEOP),  Andishe Attarbaschi (BFM-Austria),  Anja Möricke 
(BFM-Germany), Caroline Piette (EORTC), Shlomit Barzilai (INS),  Der-Cherng Liang (TPOG), Elizabeth Chalmers 
(UKALL), Motohiro Kato (Japan), Sima Jeha (SJCRH). 
Pneumocystis jirovecii pneumonia  Consensus definition by PTWG Rachael Hough (UKALL), Pat Brown (COG), Mette Levinsen (NOPHO), Sima Jeha (SJCRH), Ting-Chi Yeh (TPOG). 
Treatment-related mortality 
Addressed by other international 
working group6 
Not addressed by PTWG 
Invasive fungal infection 
Addressed by other international 
working group 
Not addressed by PTWG 
Transferal to intensive care unit  
Influences by logistics and local 
resources 
Not addressed by PTWG 
Severe local infections, including fasciitis 
Multiple causes, new definition not 
attempted 
Not addressed by PTWG 
Severe dermatitis 
Multiple causes, new definition not 
attempted 
Not addressed by PTWG 
Non-methotrexate related organ dysfunction 
Multiple causes, new definition not 
attempted 
Not addressed by PTWG 
Other life-threatening events 
Multiple causes, new definition not 
attempted 
 
Not addressed by PTWG 
23 
 
Toxicities requiring laparotomy/laparoscopy 
Multiple causes, new definition not 
attempted 
Not addressed by PTWG 
Miscellaneous other rare SUSARs  
Multiple causes, new definition not 
attempted 
Not addressed by PTWG 
Heart failure or severe arrhythmia Defined by NCI-CTCAEv4.03 
 
Hypoglycemia Defined by NCI-CTCAEv4.03 
Psychosis Defined by NCI-CTCAEv4.03 
Myopathy Defined by NCI-CTCAEv4.03 
AIEOP = Associazione Italiana Ematologia ed Oncologia Pediatrica; BFM = Berlin-Frankfurt-Münster study group; COALL = The German Co-operative Study Group COALL for treatment of 
acute lymphoblastic leukemia; COG = US Childrens Oncology Group; CPH = Czech Working Group for Pediatric Hematology; DCOG = Dutch Childhood Oncology Group; DFCI = Dana 
Farber Cancer Institute; EORTC = European Organisation for Research and Treatment of Cancer; INS = Israel National Study; JPLSG = Japanese Pediatric Leukemia Study Group; NOPHO = 
Nordic Society for Paeditric Haematology and Oncology; SJCRH = St Jude Children’s Research Hospital; TPOG = Taiwan Pediatric Oncology Group; UKALL = United Kingdom Acute 
Lymphoblastic Leukaemia and Lymphoma Trial Group. 
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Table A2: Overview of the 14 acute toxicities addressed in childhood ALL protocols.  
 
 
Toxicity  AEIOPa BFMa* COALLa COGb 
All gr 4 reported 
DCOGc 
All gr 3-4 
reported 
DFCIc 
All gr 3-4 
reported 
EORTCc 
All gr 3-4 
reported 
JPLSGc NOPHOa SJCRHd 
Extensive 
capture  of 
gr 2-4   
TPOGd UKALLc 
Hypersensitivity 
to asparaginase 
As BFM Modified CTC.  
All grades 
(details in 
protocol 2009) 
CTC 
gr 4  
 
CTC  
gr 3,4 
CTC  
All grades 
CTC 
All grades 
CTC 
All grades 
CTC 
All grades 
CTC 
gr 3.4 that leads to 
ASP truncation 
CTC 
gr 2-4 
Allergy that 
leads to 
ASP 
truncation 
CTC 
gr 2-4 
Silent 
inactivation of 
asparaginase 
NONE NONE Defined 
in 
Protocol  
08-09 
NONE Details in 
protocol ALL11  
Defined in 
protocol 
11-001 
CTC 
gr 3,4 
(“Other”) 
NONE NONE NONE NONE NONE 
Allergic-like 
reaction to 
asparaginase 
NONE Targeted but not 
specifically 
defined 
NONE NONE NONE NONE CTC 
gr 1-4 
CTC 
All grades 
NONE CTC 
gr 2-4 
NONE CTC 
gr 3,4 
Hyperlipidemia 
 
NONE NONE NONE NONE NONE >10x UNL 
 
CTC 
gr 3,4 
(“Other”) 
CTC 
All grades 
>5xUNL CTC 
gr 2-4 
>5xUNL CTC 
gr 3,4 
Osteonecrosis 
 
Not 
specifically 
defined 
 
ARCO staging CTC  
gr 2,3,4; 
but not  
specifical
ly 
defined  
CTC 
gr 2,3,4 
CTC 
gr 3,4 
CTC 
All grades 
CTC 
Not 
specifically 
defined 
 
CTC 
All grades 
CTC 
gr 2-4 
CTC 
gr 2-4 
ECOG CTC 
gr 3,4 
targeted reporting if 
symptomatic & 
radiologically 
confirmed 
Asparaginase-
associated 
pancreatitis 
Defined as 
BFM 
Abdominal pain & 
amylase/lipase 
>2xUNL 
CTC  
gr 2,3,4 
 
CTC 
gr 2,3,4 
(amylase>2xUNL) 
CTC 
gr 2,3,4 
(amylase>3xUN
L >72h) 
CTC 
All grades 
(amylase>3
xUNL 
>72h) 
CTC 
gr 3,4 
CTC 
All grades 
Abdominal pain & 
amylase/ lipase 
>3xUNL & imaging 
(2 of 3) 
CTC 
gr 2-4 
Severe: 
pain & 
amylase 
>3xUNL 
>72h 
CTC 
gr 2-4 
Severe: as 
SJCRH 
CTC 
gr 3, 4  
Details in protocol 
Arterial 
hypertension 
NONE NONE NONE CTC 
gr 4 
CTC 
gr 2,3,4 
CTC 
gr 3,4 
CTCgr 3-4 
(“Other”) 
CTC 
gr 4 
CTC 
gr 4 
CTC 
gr 2-4 
CTC 
gr 4 
CTC 
gr 3,4 
Posteror 
reversible 
encephalopathy 
syndrome  
CTCa  
All grades 
 
Only if MRI shows  
leukencephalo-
pathy 
NONE CTC 
gr 4 
CTC 
gr 3,4 
CTC 
gr 3,4 
CTC 
gr 1-4 as 
leukoence-
phalopathy 
CTC 
gr 4 
Very detailed 
definition in 
protocol 
CTC 
gr 2-4 
NONE CTC 
gr 3,4 as leuko-
encephalopathy 
Seizure 
 
NONE  Any CTCAE  
gr 2,3,4 
CTC 
gr 2,3,4 
CTC 
gr 3,4 
CTC 
Reported if 
life-
threatening 
CTC 
gr 1-4 
CTC 
gr 4 
CTC 
gr 2-4 
CTC 
gr 2-4 
ECOG CTC 
gr 3,4 
Report if associated 
with it MTX 
Depressed level 
of consciousness 
As BFM CTCAE gr 3,4 NONE Only CTC gr 3-4  
encephalopathy 
NONE 
Captured as 
CTC ‘Other 
severe toxicity’  
gr 3,4  
CTC 
gr 3,4 
CTC 
gr 3-4 
(“Other”) 
CTC 
All grades 
Only coma 
registered 
CTC 
gr 2-4 
NONE CTC 
gr 3,4 
Methotrexate-
related, stroke-
CTCa  
All grades 
Subacute neuro-
toxicity with 
NONE CTC 
All grades of 
Captured as 
CTC ‘Other 
CTC 
gr 3,4 
CTC 
gr 3-4 
CTC 
gr 4 
NONE CTC 
gr 2-4 
NONE CTC gr 3, 4  
Targeted reporting 
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like syndrome  normalization 
<2w from it MTX 
transient ischemic 
attacks 
severe toxicity’ 
gr 3,4 
(“Other”) Details in protocol 
Peripheral 
neuropathy 
NONE 
 
Only peripheral 
paralysis 
registered 
NONE Balis scale  CTC 
gr 3,4 
CTC 
gr 3,4 
CTC 
gr 3-4  
CTC 
All grade 
Only peripheral 
paralysis registered 
CTC 
gr 2-4 
NONE CTC 
gr 3, 4  
 
Severely delayed 
MTX clearance 
AE: 
h42>5µM 
h48>3µM  
 
 
Normal 
(projected) 
clearance defined 
at h24, h36, h42, 
h48, h54 
NONE NONE NONE  CTC 
gr 3,4 
CTC 
gr 3,4 
(“Other”) 
Concentrati
on h42, 
h48, h66 
captured. 
h42 >10 µM Research-
based 
capturee 
h42 >10 
µM 
NONE 
Sinusoidal 
obstruction 
syndrome  
NONE CTC NONE CTC  
gr 4 
NONE 
Captured as 
CTC ‘Other 
severe toxicity’ 
gr 3,4 
CTC 
gr 3,4 
CTC 
gr 3,4 
(“Other”) 
CTC 
gr 4 
Defined in protocol  
ALL2008 
CTC 
gr 2-4 
NONE CTC 
gr 3, 4 
Thrombo-
embolism 
AE=all 
DVT, CST, 
AT, TE 
 
AE=all DVT, 
CST, other grade 
4 thrombosis (e.g. 
pulmonary or 
aterial)  
NONE CTC 
gr 3,4   
CTC 
gr 3,4 
CTC 
All grades 
Only strokes 
CTC gr 1-4 
targeted 
 
CTC 
All grades 
Targeted but 
not specifically 
defined 
CTC 
gr 2-4 
NONE CTC 
gr 3, 4   
Details in protocol 
Pneumocystis 
jirovecii 
pneumonia  
AE only in 
case of LTI 
  
NONE, only life-
threatening 
infections 
registered 
NONE CTC 
gr 4 
NONE  
Captured as 
CTC ‘Infection’ 
CTC 
All grades 
CTC 
gr 3,4 
(“infections”) 
NONE Targeted but 
not specifically 
defined 
CTC 
gr 2-4 
NONE CTC 
gr 3, 4 
Summary of toxicity capture and definitions across protocols. Those that are specifically targeted (i.e. not part of the protocol’s general AE reporting) are in italics. The capture, definition, and 
reporting strategies are detailed to various degrees in the protocols. All groups report toxic death (CTCAE grade 5); *=Austria, Czech Republic, and Israel use the BFM protocol and have 
identical toxicity strategies; AE=adverse event; ARCO=Association Research Circulation Osseous staging system; ASP=asparaginase; AT=arterial thrombosis; Balis=Balis scale for grading of 
peripheral neuropathy 23; CST=cerebral sinus venous thrombosis; CTC=US National Cancer Institute Common Toxicity Criteria for Adverse Events; DVT=deep venous thrombosis; ECOG=US 
Eastern Cooperative Oncology Group criteria; gr=grades; h=hour; it=intrathecal; LTI=life-threatening infection; NONE=Not specifically captured; Other=CTC graded in group of “other” 
toxicities; TE=thromboembolisms; UNL=upper normal limit; a=CTC version not specified; b= CTC version 4 - COG protocols require routine reporting of all grade 4 non-hematologic AEs in 
addition to the targeted toxicities; C= CTC version 4; d=CTC version 3; e=captured as part of professor Mary Rellings research programme at St Jude Children’s Research Hospital. 
AIEOP = Associazione Italiana Ematologia ed Oncologia Pediatrica; BFM = Berlin-Frankfurt-Münster study group; COALL = The German Co-operative Study Group COALL for treatment of 
acute lymphoblastic leukemia; COG = US Childrens Oncology Group; CPH = Czech Working Group for Pediatric Hematology; DCOG = Dutch Childhood Oncology Group; DFCI = Dana 
Farber Cancer Institute; EORTC = European Organisation for Research and Treatment of Cancer; INS = Israel National Study; JPLSG = Japanese Pediatric Leukemia Study Group; NOPHO = 
Nordic Society for Paeditric Haematology and Oncology; SJCRH = St Jude Children’s Research Hospital; TPOG = Taiwan Pediatric Oncology Group; UKALL = United Kingdom Acute 
Lymphoblastic Leukaemia and Lymphoma Trial Group. 
